FindTrial
Sign In

Efficacy of Double Carbapenem regimen against Carbapenem resistant Enterobacteriaceae infections

A single centre, prospective, observational study to evaluate the efficacy and safety of Colistin with double carbapenem regimen versus other antimicrobial combinations with colistin for treatment of carbapenem resistant enterobacteriaceae infections.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/01/030762
Enrollment
72
Registered
2021-01-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A415- Sepsis due to other Gram-negativeorganisms

Interventions

None listed

Sponsors

Roopali Somani
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 years and above of any gender 2. Inpatients with positive culture for Carbapenem Resistant Enterobactericeae 3. Subjects willing to comply with study related procedures

Exclusion criteria

Exclusion criteria: 1. Patients with history of Epilepsy 2. Patients with Creatinine Clearance <30 ml/min 3. Patients with any comorbidities that is known to affect the study outcome 4. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Proportion of patients developing microbiological and clinical cure at Day 14 and Day 28 in treatment A and treatment B groups.Timepoint: 14 and 28 days—

Secondary

MeasureTime frame
1. Time to microbiological and time to clinical cure in the treatment groups 2. Incidence of adverse effects among the treatment groups.Timepoint: 5, 7,14 and 28 days—

Countries

India

Contacts

Public ContactRoopali Somani

Nizams institute of medical sciences, hyderabad

drarunadonepudi@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026